Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04474678
Other study ID # 1564/2017
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2020
Est. completion date December 31, 2023

Study information

Verified date January 2024
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the main goal is to implement and evaluate a novel, evidence-based psycho-educative program for children in oncological care. Patients are provided with booklets tailored to each specific stage of their treatment. Among other factors, children's emotional well-being is evaluated as well as feasibility. The study is carried out at multiple sites across Austria, Germany and Italy/South Tirol.


Description:

It is well documented that the prevalence of mental disorders in childhood cancer survivors is twice to quadruple compared to healthy controls. Effects range from impaired emotional balance, fear of recidivisms, helplessness, depression to post traumatic stress disorder. As a basis for interventions to preventively address these issues and moreover, to achieve defined psychosocial goals in the field of paediatric oncology, guidelines and standards systematically describe stressors and resources in particularly challenging situations. Nevertheless, despite these guidelines, actual care is quite heterogenous due to differences in setting, provision and profession. Studies show that integrated models of psychosocial care yield better outcomes. Integrated care systems can enhance patient satisfaction, increase perceived quality of care, and enable access to services and reduce service costs. Highly complex, system-wide interventions such as models of integrated care represent considerable challenges for operationalisation of relevant factors and evaluation of whole processes compared to single interventions (e.g. relaxation techniques). Quality improvement (QI) is an iterative process designed to make controlled changes within the health care delivery system to provide patients with high-quality care that meets both their expectations and needs. In terms of quality assurance, this QI Project aims to operationalize recommendations of the S3 guideline for psychosocial care which results in a combined process- and patient-oriented intervention and evaluation tool - bridging the gap between standards/evidence and clinical practice. The "Onco-Mini-Version" of "My Logbook - I know my way around" already comprises a Starter-Kit and 8 booklets, which cover at least one main issue of every treatment phase: initial contact, medical assessment (MRI), supportive therapy (chemotherapy, radio therapy), rehabilitation and after-care. All interventions are carried out by a clinical psychologist or psychosocial staff specialized in pediatric psychooncology and are understood as part of an integrated care system. Every booklet provides practical materials with enhanced stimulating elements to encourage the child to explore actively. The booklets are structured in two face-to-face sessions covering psychoeducational, activity & practice and reflective aspects. The core of this QI project is a multilevel and interdisciplinary approach characterized by iterative processes. PDSA (Plan, Do, Study, Act) cycles were applied in all steps of conceptualization and implementation of this project. It aims to systematically improve psychosocial care of pediatric cancer patients through being implemented in a large number of hospitals in the German-speaking world. The proposed multicenter pilot phase promotes emotional well-being and level of information of the child during treatment through transfer of knowledge and coping skills. Moreover, it addresses feasibility of the tool but also the impact of medical procedures on feasibility. In the long term, the program is intended to help attenuate psychological late effects of oncological conditions and their treatments.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 6 Years to 14 Years
Eligibility Inclusion Criteria experimental group: - currently or formerly treated for oncological condition - children/families at standard risk (Pediatric Psychosocial Preventative Health Model (PPPHM)) - at least average cognitive abilities (as measured via intelligence test) Inclusion Criteria control group: - currently or formerly treated for oncological condition Exclusion Criteria: - non-German speaking - Major vision impairments - Major auditive impairments

Study Design


Intervention

Other:
"My Logbook! - I know my way around!"
Special issues/booklets of "My Logbook - I know my way around!" - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide ("My Logbook") to accompany the child throughout all stages of oncological treatment.

Locations

Country Name City State
Austria Medical University Graz Graz
Austria Kepler Universitätsklinikum Linz Oberösterreich
Austria Rehabilitationszentrum St. Veit im Pongau St. Veit Salzburg
Austria Medical University of Vienna Vienna
Austria St. Anna Kinderspital Vienna
Germany Klinik Bad Oexen Bad Oeynhausen
Germany Charité - Universitätsmedizin Berlin Berlin
Germany Luca-Dethlefsen-Hilfe e.V. Bielefeld
Germany Universitätsklinikum Carl Gustav Carus Dresden Dresden
Germany Universitätsklinikum Essen Essen Nordrhein-Westfalen
Germany Universitätsklinikum Frankfurt am Main Frankfurt am Main Hessen
Germany Universitätsklinikum Hamburg-Eppendorf Hamburg
Germany Medizinische Hochschule Hannover Hannover Niedersachsen
Germany Universitätsklinikum des Saarlandes Homburg Saarland
Germany Universitätsklinikum Leipzig Leipzig Sachsen
Germany Universitätsklinikum Mannheim Mannheim
Germany Universitätsklinikum Münster Münster Nordrhein-Westfalen
Germany Universitätsklinikum Regensburg Regensburg
Germany Universitätsklinikum Tübingen Tübingen
Germany Universitätsklinikum Würzburg Würzburg
Italy Ospedale di Bolzano Bolzano Trentino-Alto Adige
Switzerland Inselspital, Universitätsspital Bern Bern

Sponsors (28)

Lead Sponsor Collaborator
Medical University of Vienna Charite University, Berlin, Germany, Cnopfsche Kinderklinik, Nürnberg, Goethe University, Hannover Medical School, Insel Gruppe AG, University Hospital Bern, Kepler University Hospital, Klinik Bad Oexen, Germany, Krankenhaus Bozen, Leuwaldhof St.Veit (Kinder- und Jugendreha), Luca-Dethlefsen-Hilfe e.V., Medical University of Graz, Salzburger Landeskliniken, St. Anna Kinderspital, Austria, Staedtisches Klinikum Karlsruhe, Universitätsklinikum Hamburg-Eppendorf, Universitätsklinikum Köln, Universitätsklinikum Leipzig, Universitätsmedizin Mannheim, University Hospital Carl Gustav Carus, University Hospital Erlangen, University Hospital Muenster, University Hospital Regensburg, University Hospital Schleswig-Holstein, University Hospital Tuebingen, University Hospital, Essen, University Hospital, Saarland, Wuerzburg University Hospital

Countries where clinical trial is conducted

Austria,  Germany,  Italy,  Switzerland, 

References & Publications (7)

Baxter S, Johnson M, Chambers D, Sutton A, Goyder E, Booth A. The effects of integrated care: a systematic review of UK and international evidence. BMC Health Serv Res. 2018 May 10;18(1):350. doi: 10.1186/s12913-018-3161-3. — View Citation

Kazak AE, Abrams AN, Banks J, Christofferson J, DiDonato S, Grootenhuis MA, Kabour M, Madan-Swain A, Patel SK, Zadeh S, Kupst MJ. Psychosocial Assessment as a Standard of Care in Pediatric Cancer. Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S426-59. doi: 10.1002/pbc.25730. — View Citation

Koch U, Mehnert A, Harter M. [Chronic somatic disorders and psychological comorbidity]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jan;54(1):1-3. doi: 10.1007/s00103-010-1196-7. No abstract available. German. — View Citation

Schröder HM, Lilienthal S, Schreiber-Gollwitzer BM, Griessmeier B, Leiss U. Psychosoziale Versorgung in der Pädiatrischen Onkologie und Hämatologie. PSAPOH (Hg.). 2013.

Schurman JV, Gayes LA, Slosky L, Hunter ME, Pino FA. Publishing quality improvement work in Clinical Practice in Pediatric Psychology: The "why" and "how to". Clinical Practice in Pediatric Psychology. 2015 Mar; 3(1):80.

Scialla MA, Canter KS, Chen FF, Kolb EA, Sandler E, Wiener L, Kazak AE. Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States. Pediatr Blood Cancer. 2018 Mar;65(3):10.1002/pbc.26869. doi: 10.1002/pbc.26869. Epub 2017 Oct 28. — View Citation

Stuber ML, Meeske KA, Krull KR, Leisenring W, Stratton K, Kazak AE, Huber M, Zebrack B, Uijtdehaage SH, Mertens AC, Robison LL, Zeltzer LK. Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer. Pediatrics. 2010 May;125(5):e1124-34. doi: 10.1542/peds.2009-2308. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Emotional well-being, T1 Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. Based on the medical therapy protocol, after medical consultation, prior to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Emotional well-being, T2 Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. Post to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Emotional well-being, T3 Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. During, but before completion of treatment; prior to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Emotional well-being, T4 Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. During, post to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Emotional well-being, T5 Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. During, but before completion of treatment - through study completion or end of medical treatment, an average of 1 year
Primary Knowledgeability, T1 Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. Based on the medical therapy protocol, after medical consultation, prior to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Knowledgeability, T2 Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. Post to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Knowledgeability, T3 Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. During, but before completion of treatment; prior to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Knowledgeability, T4 Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. During, post to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year
Primary Knowledgeability, T5 Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. During, but before completion of treatment - through study completion or end of medical treatment, an average of 1 year
Primary Feasibility of program Rating of feasibility of the program by medical staff Feasibility of program is evaluated following the second session which on average takes place one to six months after start of the treatment of the special issue (booklet). - through study completion or end of medical treatment, an average of 1 year
Secondary Intelligence test Patients are administered a standardized intelligence test, dependent on their age, e.g.
Wechsler Intelligence Scale for Children IV WISC-IV, Petermann & Petermann, 2014 or other comparable methods due to clinical standards
During the first two months from diagnosis or start of psychosocial treatment - up to three Months
Secondary Strengths and Difficulties Questionnaire (SDQ; Goodman, 1999) The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire about 3-16 year olds. During the first two months from diagnosis or start of psychosocial treatment - up to three Months
Secondary KINDLR (Ravens-Sieberer & Bullinger, 2000) The KINDLR is a standardized questionnaire for the assessment of quality of life in children and adolescents. During the first two months from diagnosis or start of psychosocial treatment - up to three Months
Secondary Questionnaire on Health Competence in Children and Adolescents, (Weiler, Fohn, Pletschko, Schwarzinger, & Leiss, 2017) Questionnaire for the assessment of health competence in children and adolescents During the first two months from diagnosis or start of psychosocial treatment - up to three Months
Secondary Medical information Diagnosis, date of diagnosis, pre-existing conditions, secondary conditions, form of treatment/therapy, psychiatric diagnoses, neurological status Within the first week of treatment - up to three Months
Secondary Demographic data Age of patient, sex, parents' education, parents' profession, school form, mother language of patient During the first two months from diagnosis or start of psychosocial treatment - up to three Months
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT04092803 - Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu N/A
Active, not recruiting NCT02530463 - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Phase 2
Completed NCT00948064 - Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 2
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Recruiting NCT03948529 - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation Phase 2
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Active, not recruiting NCT02723994 - A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02469415 - Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Phase 2
Recruiting NCT04856215 - 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia Phase 2
Recruiting NCT06155188 - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia N/A
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Completed NCT01212926 - Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A
Completed NCT00858117 - A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL Phase 2